,trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['destiny-04', 'biomarker']
destiny-04 offers great promise for her-2 ihc 1+/2+ patients but also opens the door for more sensitive biomarker quant approaches than old-fashioned ihc. great to see the potential of high precision targeted mass spec assays as a solution here. #asco22 #asms2022 
Enabling drug discovery through next-generation #proteomics CBO @Biognosys | Prior-life principal at oncology-focused VC @NextechInvest | Immunologist